

Prospective Study

Longitudinal MIBC Collection with Matched Tissue and Blood-Based Specimens

Prospective pre- and post-treatment biospecimen collection supporting muscle-invasive bladder cancer research.



Challenge

Muscle-invasive bladder cancer (MIBC) research presents several challenges, including tumor heterogeneity, limited tissue availability, and treatment-related changes in tumor biology. These factors can make it difficult to identify and validate reliable biomarkers or predict individual responses to therapy.

Longitudinal studies using matched tissue and blood-based specimens can provide a more complete view of disease progression and treatment response. High-quality, well-annotated specimens—including formalin-fixed, paraffin-embedded (FFPE) tissue, plasma, serum, and other blood-based samples—are particularly valuable for biomarker discovery, liquid-biopsy and circulating tumor DNA (ctDNA) research, treatment-response studies, and diagnostic development.

Solution



Study enrollment

Prospective longitudinal collection from 45 participants at one clinical site outside the United States



Fresh Logistics

Fresh blood specimens delivered within 72 hours of collection



Collection Timepoints

Pre-treatment and four to eight weeks after treatment initiation



Matched Specimens

FFPE tissue and blood-based specimens, including whole blood collected across multiple tubes and plasma

Results

Boca Bio supported the longitudinal MIBC collection while adhering to the sponsor's strict inclusion and exclusion criteria. The collection was completed ahead of schedule and provided matched specimens across multiple treatment timepoints, supported by extensive clinical data covering each participant's diagnosis and treatment course.

- Completed a prospective longitudinal collection from 45 participants
- Enrolled patients with Stage II–IV non-metastatic MIBC*
- Collected specimens at pre- and post-treatment timepoints
- Provided matched FFPE tissue and blood-based specimens
- Delivered fresh blood from outside the United States within 72 hours of collection
- Supplied extensive diagnosis and treatment data
- Followed strict inclusion and exclusion criteria

